Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a rare lung disease characterized by the gradual scarring of lung tissue, which makes it increasingly difficult to breathe over time.
Idiopathic Pulmonary Fibrosis: CMR316 Safety Study
We are assessing the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. This study aims to understand how well the treatment is tolerated.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM
Division of Clinical Airway Research
Hannover, Germany
Sponsor: The Scripps Research Institute
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.